---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-23-000006"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:36:42.745811+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amneal Q4 revenue $610M (+14% YoY), adj. EBITDA $154M; FY23 guidance $2.25-2.35B

## Summary
- Q4 2022 net revenue $610M (+14% YoY); GAAP net loss $4M ($0.03 loss per share).
- Q4 adjusted net income $71M, adjusted EBITDA $154M (+26% YoY), adjusted diluted EPS $0.23.
- Full year 2022 net revenue $2.21B (+6% YoY); GAAP net loss $130M ($0.86 loss per share) including $263M Opana litigation charge.
- Full year adjusted EBITDA $514M (+$2M YoY), adjusted diluted EPS $0.68.
- 2023 guidance: net revenue $2.25-2.35B, adjusted EBITDA $500-530M.

## SEC filing metadata
- accession: 0001723128-23-000006
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/0001723128-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/amrx-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-23-000006
- JSON: https://secwatch.observer/filing/0001723128-23-000006.json
- Plain text: https://secwatch.observer/filing/0001723128-23-000006.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $610 million, net income $4 million, EPS $0.03. Guidance initiated.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $610 million
  - Net income: $4 million
  - EPS: $0.03
  - Guidance: initiated
  - Result: reported results
  source text: Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/0001723128-23-000006-index.htm
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: revenue $2.21 billion, net income $130 million, EPS $0.86. Guidance initiated.
  - Period: the year ended December 31, 2022
  - Revenue: $2.21 billion
  - Net income: $130 million
  - EPS: $0.86
  - Guidance: initiated
  - Result: reported results
  source text: Full Year 2022 Net Revenue of $2.21 billion; GAAP Net Loss of $130 million; Diluted Loss per Share of $0.86
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/0001723128-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.